Key result
Apolipoprotein D mRNA expression was upregulated 5.88-fold in failing human hearts compared with non-failing hearts, with elevated plasma levels also observed in heart failure patients.
Why the study?
The expression pattern of Apo D and its potential as a new marker in human end-stage heart failure were unclear.
Does Apolipoprotein D expression differ between patients with end-stage heart failure and non-failing controls?
Case-Control (n=12)
Does Apolipoprotein D expression differ between patients with end-stage heart failure and non-failing controls?
Apolipoprotein D is significantly upregulated in the myocardium and plasma of patients with end-stage heart failure, suggesting its potential as a novel circulating biomarker.
Answers are grounded in this paper and cite their sources.
Elevated Apolipoprotein D may indicate a novel heart failure biomarker; leaves open its clinical utility pending prospective validation.
Apolipoprotein D (Apo D) is reported to be in close association with developing and mature blood vessels, and involved in enhanced smooth muscle cell migration after injury. This study was designed to clarify the expression pattern of Apo D and the possibility of Apo D as a new marker in human end-stage heart failure. Individual RNA samples obtained from independent left ventricular tissue of six heart failure patients derived from cardiomyopathies of different aetiologies during cardiac transplantation and six non-failing control subjects were hybridized to the gene microarray containing, in total, 35 000 well-characterized Homo sapiens genes. Apo D was one of the highly expressed genes (3.3-fold upregulated) detected by microarray, which was further confirmed by quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR) (5.88-fold upregulated) in failing hearts compared with non-failing hearts. Both Western blotting and immunohistochemistry analyses also demonstrated the higher levels of Apo D protein in failing hearts. Importantly, we observed elevated levels of plasma Apo D in heart failure patients compared with non-failing control subjects. We demonstrated, for the first time to our knowledge, that Apo D was highly expressed in the mRNA and protein levels in human failing hearts compared with non-failing hearts. Furthermore, our finding of elevated plasma Apo D levels in patients with heart failure provides clues that Apo D may act not only as a cardiac molecular marker but also as a circulating biomarker in patients with heart failure.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2008) conducted a case-control in End-stage heart failure (n=12). End-stage heart failure vs. Non-failing control subjects was evaluated on Apolipoprotein D (Apo D) expression (5.88-fold upregulated). Apolipoprotein D mRNA expression was upregulated 5.88-fold in failing human hearts compared with non-failing hearts, with elevated plasma levels also observed in heart failure patients.
Synapse has enriched 10 related papers. Consider them for comparative context: